

Senzime recruits General Manager to lead US operations

Press release: Uppsala, December 18, 2019. Senzime AB (publ) today announces that the company has recruited Chris Estes as General Manager of the US operations. Chris takes office on January 6, 2020 and will also be a member of the Senzime AB Executive Management team.

Chris Estes has over twenty years' experience from Management positions in the Medical Device industry. Chris worked 10 years at Medtronic in different senior roles, most recently as Regional Vice President responsible for Respiratory and Monitoring Solution Sales. He joins Senzime from a position as President and General Manager for the North America operations at SenTec Inc. Chris holds a B Sc in Respiratory Care and Business Management from the University of Missouri, Columbia.

"We are extremely pleased to have Chris on board to lead the development of our US operations in this intense and exciting phase for Senzime. With his background and experience, we have the right management in place to successfully drive TetraGraph sales in North America", says Pia Renaudin, CEO Senzime.

Senzime AB:s wholly owned subsidiary Senzime Inc. is registered in Florida since early December. The sales of TetraGraph will be driven through both distributors and direct sales. Several TetraGraph studies have been conducted in Florida at the The Mayo Clinic in Jacksonville.

For further information, please contact:

Pia Renaudin, CEO of Senzime AB

Tel: +46 (0)70-813 34 17, email: pia.renaudin@senzime.com

TO THE EDITORS

About Senzime

Senzime develops and markets patient monitoring systems, driven by unique algorithms and sensors. The company's system is called TetraGraph, a medical technology device that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, info@fnca.se is Certified Adviser for Senzime. www.senzime.com